Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

Fig. 3

Maraba boosting alters the inflammatory tumor microenvironment, however tumors escape immune clearance via multiple mechanisms. a OVA-specific CD8+ T cells were enumerated in the peritoneal TME on d15 post therapy onset (n = 7). b Representative FACs plots depicting % OVA-specific CD8+ T cells by tetramer staining and corresponding IFN-γ production following ex vivo OVA257–264 peptide stimulation in matched spleen and TME samples on d15 following MIS416 Vax + MRB-OVA. c IE9-mp1 tumor progression in mice using a d12 therapeutic model following MIS416 Vax alone () or in combination with MRB-CONT (♦) or MRB-OVA () (n = 3). d Representative FACs plots measuring OT-1 T cell activation (based on CD69 upregulation) following co-culture with IE9-mp1 tumor explants collected at endpoint (blue histograms). Gray histograms show CD69 surface expression on naïve OT-1 cells cultured alone in parallel. Data presented as mean ± SEM

Back to article page